Up 9%: Time to Buy BioDelivery Sciences International, Inc.?

BioDelivery Sciences  (NASDAQ: BDSI  ) shareholders got some welcome good news today, with positive phase 3 top-line data for BEMA buprenorphine sending shares up 9% as of this writing.

The drug provided a statistically significant improvment in chronic pain relief versus placebo, and the trial's completion triggered a $10 million payment from commercialization partner Endo International  (NASDAQ: ENDP  ) . So, considering today's good news, should investors think about buying BioDelivery stock?

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give more details on the drug and whether this makes BioDelivery Sciences a stock to buy.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 10, 2014, at 10:37 AM, whofeelsit wrote:

    Did these guys actually do any research before they turned the camera on? They clearly know nothing about this company, save a few notes that were jotted down on that paper that guy on the right kept looking at.

    Protip: you lost the audience at the first "um."

  • Report this Comment On August 07, 2014, at 11:20 AM, MayTepper wrote:

    BioDelivery: Clonidine Gel Is Significantly Undervalued By Investors, Says Roth Capital http://bit.ly/V0Tvys

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3020287, ~/Articles/ArticleHandler.aspx, 8/21/2014 12:47:18 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement